MA Star Ratings Drop For 2023

Experts’ predictions from 2021 came true on Thursday (Oct. 6) when CMS’ 2023 star ratings for Medicare Advantage showed only about half of the plans for next year will have at least a four-star rating. Meanwhile, CMS says it will be adjusting only one measure due to COVID-19 and it increased the weight of the patient experience/complaints and access measures. Last year, CMS touted the jump in Medicare Advantage plans’ star ratings -- nearly 70% of plans earned four or...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 10/13/2022
CMS Volume: 
Vol. 25, No. 41




Nursing Home CNA Training Waiver Ends, CMS OKs States’ Requests Instead

Nursing homes are upset that CMS on Thursday (Oct. 6) rejected their request to extend through the public health emergency and beyond a pandemic waiver allowing facilities to employ temporary nurse aides for more than four months without certified nurse aid training. The agency instead approved waivers in 15 states, which last no longer than the end of the PHE, leaving nursing homes in some parts of the country without the ability to take advantage of the staffing flexibility. The...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
Email Subject Line: 
Breaking Nursing Home Staffing News
CMS Issue: 
Inside CMS - 10/13/2022
CMS Volume: 
Vol. 25, No. 41
Author: 


HHS Still Considering March-In Rights Amid Calls For Petition Decision

The Biden administration’s handling of a petition for the government to “march in” on the patents of the prostate cancer drug Xtandi will likely set a precedent for whether the government is willing to use march-in rights under the Bayh-Dole Act to lower prices for drugs developed with taxpayer funding, according to 62 consumer groups in support of the petition . Xtandi was developed with funding from the U.S. Army and the National Institutes of Health, and it costs three...
Article Type: 
Site Name: 
InsideHealthPolicy.com
IDP Issue: 
Inside Drug Pricing - 10/10/2022
IDP Volume: 
Vol. 5, No. 41
Author: 




Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.